Compare Jones Lang LaSalle Inc (JLL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Moderna, Inc. — how do they compare? Jones Lang LaSalle Inc trades at $302.07 (market cap $13.95B), while Moderna, Inc. trades at $221.61 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 5.6× Jones Lang LaSalle Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Moderna, Inc. for 59 Days on average.
| JLL | MRNA | |
|---|---|---|
Market Cap | $13.95B | $78.65B |
Volume | 457,462 | 37,373,437 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $203.46 |
52-Week Low | $280.16 | $22.36 |
Typical Hold Time | 71 Days | 59 Days |
Enterprise Value | $16.71B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.99, up 1.12% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $26.12B in 2025, and net income improved to $792.10M. Analyst consensus is bullish with a $450.50 price target, though technical indicators show resistance near $300.
JLL presents a compelling growth opportunity with improving profitability and a reasonable valuation (P/E 14.54). Risks include market volatility and execution challenges in real estate services. The stock's upside potential is supported by analyst optimism and strong cash flow trends, but investors should monitor Q3 earnings for confirmation of growth trajectory.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
